The recommendations, published in JAMA, are designed to help clinicians have practical, evidence-based conversations about e-cigarettes rather than treating them as an automatic alternative to established medications. The authors stress that the objective is not to promote nicotine use. Instead, it is to move people away from combustible cigarettes, whose smoke contains thousands of chemicals generated when tobacco is burned. Many of those combustion products, rather than nicotine itself, drive the development of cancer, cardiovascular disease and chronic lung disease.

Developed by the Harm Reduction Work Group of the Society for Research on Nicotine and Tobacco’s Treatment Research Network, the guidance recommends a patient-centered “menu of options.” This approach asks clinicians to consider a smoker’s medical history, previous quit attempts, treatment preferences and likelihood of following a particular plan. When patients have no strong preference, FDA-approved medications such as nicotine-replacement therapy, varenicline or bupropion remain appropriate starting points. However, patients who prefer nicotine e-cigarettes should not necessarily be required to fail other treatments before trying them.

The recommendation reflects the principle of shared decision-making, in which clinicians explain potential benefits, limitations and uncertainties while patients participate actively in selecting treatment. Nicotine e-cigarettes deliver nicotine through an aerosol rather than tobacco smoke. Because the device does not burn tobacco, users generally encounter substantially lower levels of many toxic chemicals than they would from cigarettes. That difference is central to the concept of harm reduction: replacing a far more hazardous source of nicotine with a lower-risk, though not risk-free, product.

Evidence summarized in the recommendations includes high-certainty findings from Cochrane systematic reviews indicating that nicotine e-cigarettes can help some adults stop smoking and may outperform nicotine patches or gum in achieving cessation. Other reviews have reported effectiveness comparable to certain FDA-approved smoking-cessation medications. The researchers caution, however, that effectiveness varies among individuals. Some smokers do not quit with e-cigarettes, while others continue using both cigarettes and e-cigarettes for extended periods, a pattern known as dual use that may limit health benefits.

The guidance therefore emphasizes complete transition away from combustible cigarettes as quickly as possible. A smoker who continues to inhale cigarette smoke remains exposed to combustion-related toxins, even if e-cigarette use is added. Clinicians are encouraged to monitor progress, reinforce cigarette abstinence and provide follow-up care. They should also explain that e-cigarettes are intended in this context for adults who currently smoke, not for young people, nonsmokers or anyone who has never used tobacco.

Long-term safety remains an important uncertainty. Although e-cigarettes have been available for years, researchers do not yet have the decades of observational data needed to fully characterize risks that may emerge after prolonged exposure. E-cigarette aerosols can contain nicotine, ultrafine particles, flavoring chemicals, metals and other substances, depending on the device and liquid formulation. Nicotine itself is highly addictive and can affect heart rate and blood pressure, even though it is not the primary cause of smoking-related cancers. For that reason, the authors describe e-cigarettes as a cessation tool with trade-offs, not as harmless consumer products.

The recommendations also call for behavioral counseling alongside medication or nicotine e-cigarette use. Smoking is not solely a pharmacological dependence; it is also a learned behavioral pattern linked to routines, environments and emotional states. A smoker may associate nicotine with morning coffee, driving, alcohol or stress. Counseling can help patients identify these cues, establish a quit date or reduction plan, manage cravings and develop alternative behaviors. Combining behavioral support with pharmacological treatment has long been considered one of the most effective strategies for improving the chances of sustained cessation.

Researchers from the Medical University of South Carolina’s Hollings Cancer Center contributed to the guidance, including Alana Rojewski, Tracy Smith, Mariel Bello, Matthew Carpenter and Erin McClure. They say the recommendations answer a question clinicians have repeatedly raised: how to discuss e-cigarettes responsibly when patients ask whether they can help them quit. The authors’ central message is that clinicians should present accurate information without endorsing a single product, while keeping the immediate health priority clear—helping adult smokers stop using combustible cigarettes and reducing their risk of tobacco-related disease.

Subject of Research: People

Article Title: Nicotine E-Cigarettes for Cigarette Smoking Cessation: Recommendations to US-Based Clinicians

News Publication Date: 30-Jul-2026

Web References: JAMA article; Society for Research on Nicotine and Tobacco Treatment Research Network; Cochrane systematic review; MUSC Hollings Cancer Center

References: DOI: 10.1001/jama.2026.13087

Image Credits: Medical University of South Carolina

Keywords: smoking cessation, nicotine e-cigarettes, tobacco harm reduction, nicotine replacement therapy, combustible cigarettes, tobacco-related disease, behavioral counseling, public health, addiction science, electronic cigarettes

E-cigarettes, or electronic nicotine delivery systems, have surged in popularity over recent years, particularly among young adults and adolescents. The initial perception of e-cigarettes as a safer alternative to traditional cigarettes has become nuanced as research emerges about their potential health impacts. As these tobacco products gain traction, understanding their effect on public health becomes increasingly crucial, and the knowledge— or lack thereof— among medical students is a pivotal concern worth addressing.

The systematic survey involved a representative sample of Australian medical students, who were queried about their knowledge of e-cigarettes, including their pharmacological mechanisms, health risks, regulatory status, and their implications for smoking cessation. Alarmingly, the results indicated that a considerable percentage of students felt ill-prepared to counsel patients on e-cigarette use. This raises questions about the adequacy of current medical education curricula in addressing emerging public health issues.

The researchers utilized a cross-sectional methodology that facilitated the collection of data from various medical schools across Australia. This design provided a broad perspective, capturing the diversity in knowledge and attitudes towards e-cigarettes from students at different stages of their medical training. The comprehensive nature of the survey revealed that misconceptions about the safety and efficacy of e-cigarettes were widespread among the cohort, ultimately highlighting the need for targeted educational interventions.

Respondents were also questioned about their personal experiences and exposure to e-cigarettes. Interestingly, the findings suggested a dichotomy; while many students reported having friends or family who used e-cigarettes, this personal familiarity did not necessarily translate into a correct understanding of the device’s health impacts. This disconnect further emphasizes the critical role educational frameworks play in equipping future healthcare professionals with accurate information on emerging health-related trends.

One noteworthy aspect of the study was the exploration of the sources through which students acquire information about e-cigarettes. A large proportion indicated reliance on social media and peer discussions rather than scholarly or scientifically-backed resources. This trend underscores a growing concern that misinformation propagated through non-academic channels could severely hinder the clinical decision-making processes of future healthcare providers.

The implications of these findings extend beyond the individual students; they reflect broader societal trends with significant ramifications for public health policy. As e-cigarette use continues to rise, the lack of adequate knowledge among healthcare professionals may lead to ineffective advice being given to patients, further complicating efforts to reduce tobacco use rates. This research serves as a clarion call for medical educators to bolster their curricula in light of such new challenges and to prioritize the integration of contemporary issues into medical training.

Moreover, the research team calls into question the robustness of current educational strategies, suggesting that traditional methods may be insufficient for addressing the rapidly evolving landscape of tobacco use. Developing innovative, evidence-based teaching methodologies could be a crucial step toward fostering students’ ability to critically assess and engage with emerging public health concerns.

As educators and policymakers grapple with integrating e-cigarette education into medical training, it may be beneficial to establish collaborative initiatives between public health organizations, medical schools, and seasoned practitioners. Such partnerships could facilitate the dissemination of accurate information and promote powerful narratives reflecting the real-world implications of smoking and its alternatives.

The researchers also advocate for further studies to evaluate how medical education can most effectively evolve alongside the changing landscape of tobacco use. The benefits of ongoing research cannot be overstated; continuous data collection and analysis will be key in identifying shifts in knowledge and attitudes as new information becomes available, leading to better-prepared healthcare professionals.

In summary, the survey conducted by Mali, Chiodze, and Jersmann illuminates a critical gap in medical education related to e-cigarettes that could undermine the ability of future healthcare providers to effectively counsel and treat patients. By identifying deficiencies in current training, the research team has opened the door for significant improvements in educational strategies that can sculpt a generation of medically informed professionals adept in navigating the complexities of modern tobacco alternatives.

The need for comprehensive education on e-cigarettes among medical students is not merely a theoretical concern; it is of practical importance with direct implications for public health. As the prevalence of e-cigarette use continues to evolve, ensuring that future doctors possess the requisite knowledge and tools to respond to patient inquiries on the subject is essential. The proactive approach encouraged by the researchers aims not only to enhance the education system but also to contribute positively to the broader fabric of public health discourse.

By fostering an understanding of the intricate relationships between tobacco control, public health policy, and medical education, we can pave the way for a healthcare sector that is better equipped to tackle smoking and its various alternatives. This study is a vital catalyst for change, and it is imperative for the medical community to heed its message in order to protect the health of future generations.

Ultimately, this important research presents an opportunity for a paradigm shift in the way medical education approaches emerging health issues, specifically those surrounding e-cigarettes. A more nuanced, informed, and proactive approach to educating future medical professionals could yield profound benefits not only for those individuals but for society at large as it grapples with the challenges posed by modern tobacco products.

Subject of Research: Knowledge gap regarding e-cigarettes among Australian medical students.

Article Title: Clearing the fog: Australian medical students and the e-cigarette knowledge void – a cross-sectional survey.

Article References:

Mali, S., Chiodze, V. & Jersmann, H. Clearing the fog: Australian medical students and the e-cigarette knowledge void – a cross-sectional survey.
BMC Med Educ 25, 1612 (2025). https://doi.org/10.1186/s12909-025-08126-2

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12909-025-08126-2

Keywords: E-cigarettes, medical education, public health, tobacco control, medical students, knowledge gap, survey, Australia.

Nicotine pouches have surged as tobacco cigarette sales decline precipitously, prompting tobacco manufacturers to pivot their product portfolios. Leading brands, such as Velo and Zyn, capitalized on this downturn, positioning nicotine pouches as potentially lower-risk alternatives to combustible tobacco products. These pouches contain nicotine salts encapsulated in a white, powdery substance placed between the gum and lip, releasing nicotine while minimizing odor and smoke. Despite these products’ growing popularity, regulatory frameworks have yet to authorize them as smoking cessation tools. In January 2025, the U.S. Food and Drug Administration (FDA) granted marketing authorization for ZYN, marking the first instance of a nicotine pouch receiving such clearance. Nonetheless, the FDA explicitly prohibits marketing these pouches as cessation aids, reflecting both regulatory caution and the need for further research into their efficacy and safety.

The Rutgers study, led by Cristine D. Delnevo, director of the Rutgers Institute for Nicotine and Tobacco Studies, undertook a rigorous analysis of data obtained from the U.S. Census Bureau’s 2022-2023 Tobacco Use Supplement—a nationally representative survey involving over 110,000 adults. The survey captured detailed patterns of nicotine pouch usage alongside traditional tobacco behaviors, enabling researchers to discern both baseline prevalence rates and associations with tobacco cessation. Methodologically, the study employed sophisticated statistical analyses to assess nicotine pouch use in relation to demographic variables, prior tobacco use history, and quitting behaviors before and after 2019—the point at which nicotine pouches became widely available nationwide.

Findings revealed that despite increasing market presence, nicotine pouch use remains relatively low across the U.S. adult population. The highest usage rates appear among non-Hispanic white men, with only 2.5% reporting current use. Importantly, the study identified that nicotine pouch adoption among tobacco-naïve individuals—those who have never previously used tobacco products—is virtually nonexistent. This suggests that these products are not attracting new nicotine users but rather appealing to current or former tobacco consumers, potentially as a harm-reduction strategy.

Most strikingly, nicotine pouch use was most prevalent among adults with a history of tobacco use who recently quit smoking or e-cigarette use. This pattern intimates a possible role for nicotine pouches as a transitional aid for individuals attempting to relinquish more harmful tobacco products. Given nicotine’s high addictive potential, wholly abstaining from nicotine may be untenable for many; thus, nicotine pouches could serve as a lower-risk alternative by delivering nicotine without the toxicants generated by combustion or vaporization. However, it remains critical to underscore that these pouches are not currently endorsed as cessation devices and lack rigorous longitudinal efficacy data to substantiate such claims.

The health implications of oral nicotine pouch consumption warrant thorough exploration. Unlike carcinogens found in smoked tobacco, nicotine itself is not a direct carcinogen. Nonetheless, nicotine exerts cardiovascular effects, such as elevating blood pressure and contributing to endothelial dysfunction. The chronic health impact of sustained nicotine delivery through these pouches, particularly given the diverse formulations and nicotine concentrations available commercially, is still uncertain. Ongoing studies aim to delineate these risks, factoring in dosage, frequency, and user-specific metabolic responses.

Concerns over youth uptake amplify the complexities surrounding nicotine pouches. Data from the Centers for Disease Control and Prevention’s (CDC) 2024 National Youth Tobacco Survey indicate a modest increase in nicotine pouch use among middle and high school students, rising from 1.1% in 2022 to 1.8% in 2024. Although still low, this upward trajectory signals potential for broader youth exposure, which could subvert decades of progress in youth tobacco prevention. This trend underscores the urgent necessity for regulatory vigilance to prevent nicotine initiation among adolescents, who are more susceptible to nicotine addiction and its deleterious neurodevelopmental consequences.

In line with these concerns, Rutgers researchers have advocated for proactive regulatory measures before nicotine pouch products follow the trajectory of e-cigarettes, which rapidly proliferated with insufficient oversight, resulting in widespread youth addiction and subsequent public health crises. The researchers emphasize the importance of comprehensive surveillance of youth tobacco-use behaviors, including poly-tobacco use and substitution with flavored products, which may mask or facilitate continued nicotine dependence.

At the same time, scientists acknowledge the nuanced role nicotine pouches may play as a harm reduction tool for established adult tobacco users. Such dualistic potential—posing risks to naïve populations while offering lower-risk alternatives for current smokers—complicates public health messaging and regulatory decisions. Experts insist on distinguishing between these user groups and tailoring policies that minimize youth access yet retain potential benefits for harm reduction within adult populations.

Rutgers associate professor Mary Hrywna, a co-author of the study, highlights the emerging complexity of understanding nicotine pouch use patterns. She points out that although the data offer an initial snapshot that is somewhat reassuring, continued surveillance and granular analyses will be essential to comprehensively gauge the evolving landscape of nicotine product use. Such insights are crucial to informing regulatory standards, public health campaigns, and clinical guidelines.

The study’s timing is especially significant given the FDA’s recent authorization of multiple ZYN nicotine pouch products. These are subject to rigorous scientific review, yet critical questions linger regarding long-term safety, behavioral impacts, and potential unintended consequences in nicotine addiction dynamics. Balancing innovation in nicotine delivery systems with prudent regulatory frameworks will be vital to harnessing potential public health benefits while mitigating risks.

In summary, the burgeoning realm of nicotine pouches presents a complex challenge for tobacco control, harm reduction, and regulatory policy. Rutgers researchers’ seminal work lays a foundational understanding of who is using nicotine pouches and under what circumstances—information essential for future policy design. The key takeaways emphasize low population prevalence, predominant use among former tobacco users, inconsequential uptake among nicotine-naïve adults, potential for harm reduction, and a pressing need for vigilance to deter youth initiation. As the nicotine marketplace rapidly evolves, informed, evidence-based approaches grounded in rigorous scientific assessment will play an indispensable role in shaping a healthier future.

Subject of Research: People

Article Title: Patterns of Nicotine Pouch Use Among Adults in the US, 2022-23

News Publication Date: 8-Sep-2025

Web References:
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.31155

References:

• Delnevo CD, et al. Patterns of Nicotine Pouch Use Among Adults in the US, 2022-23. JAMA Network Open. 2025. DOI: 10.1001/jamanetworkopen.2025.31155
• FDA Press Announcement. FDA Authorizes Marketing of ZYN Nicotine Pouches. January 2025.
• CDC National Youth Tobacco Survey 2024.

Keywords: Human health, Nicotine pouches, Tobacco harm reduction, Nicotine addiction, Tobacco use patterns, Youth tobacco use, FDA regulation